LV5779B4 - Tiazolidindiona atvasinajumi ar antidiabetiskam ipasibam - Google Patents

Tiazolidindiona atvasinajumi ar antidiabetiskam ipasibam

Info

Publication number
LV5779B4
LV5779B4 LV960211A LV960211A LV5779B4 LV 5779 B4 LV5779 B4 LV 5779B4 LV 960211 A LV960211 A LV 960211A LV 960211 A LV960211 A LV 960211A LV 5779 B4 LV5779 B4 LV 5779B4
Authority
LV
Latvia
Prior art keywords
ipasib
diabetic
thiazolidinedione derivatives
thiazolidinedione
derivatives
Prior art date
Application number
LV960211A
Other languages
English (en)
Latvian (lv)
Other versions
LV5779A4 (lv
Inventor
Kanji Meguro
Takeshi Fujita
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11683488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV5779(B4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of LV5779A4 publication Critical patent/LV5779A4/xx
Publication of LV5779B4 publication Critical patent/LV5779B4/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
LV960211A 1985-01-19 1996-07-03 Tiazolidindiona atvasinajumi ar antidiabetiskam ipasibam LV5779B4 (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP808585 1985-01-19

Publications (2)

Publication Number Publication Date
LV5779A4 LV5779A4 (lv) 1996-12-20
LV5779B4 true LV5779B4 (lv) 1997-04-20

Family

ID=11683488

Family Applications (1)

Application Number Title Priority Date Filing Date
LV960211A LV5779B4 (lv) 1985-01-19 1996-07-03 Tiazolidindiona atvasinajumi ar antidiabetiskam ipasibam

Country Status (28)

Country Link
US (1) US4687777A (cg-RX-API-DMAC7.html)
EP (1) EP0193256B1 (cg-RX-API-DMAC7.html)
JP (1) JPS61267580A (cg-RX-API-DMAC7.html)
KR (1) KR920010046B1 (cg-RX-API-DMAC7.html)
CN (1) CN1003934B (cg-RX-API-DMAC7.html)
AR (1) AR240698A1 (cg-RX-API-DMAC7.html)
AT (1) ATE41931T1 (cg-RX-API-DMAC7.html)
AU (1) AU572719B2 (cg-RX-API-DMAC7.html)
BR (1) BR1100325A (cg-RX-API-DMAC7.html)
CA (1) CA1277323C (cg-RX-API-DMAC7.html)
CS (1) CS407991A3 (cg-RX-API-DMAC7.html)
DE (2) DE10199018I2 (cg-RX-API-DMAC7.html)
DK (2) DK171614B1 (cg-RX-API-DMAC7.html)
ES (1) ES8705886A1 (cg-RX-API-DMAC7.html)
FI (1) FI81098C (cg-RX-API-DMAC7.html)
GR (1) GR860124B (cg-RX-API-DMAC7.html)
HK (1) HK3692A (cg-RX-API-DMAC7.html)
HU (1) HU196795B (cg-RX-API-DMAC7.html)
IE (1) IE58928B1 (cg-RX-API-DMAC7.html)
LU (1) LU90719I2 (cg-RX-API-DMAC7.html)
LV (1) LV5779B4 (cg-RX-API-DMAC7.html)
MX (1) MX9202933A (cg-RX-API-DMAC7.html)
MY (1) MY102016A (cg-RX-API-DMAC7.html)
NL (1) NL300038I2 (cg-RX-API-DMAC7.html)
NO (1) NO163857C (cg-RX-API-DMAC7.html)
PT (1) PT81859B (cg-RX-API-DMAC7.html)
SG (1) SG105691G (cg-RX-API-DMAC7.html)
ZA (1) ZA86203B (cg-RX-API-DMAC7.html)

Families Citing this family (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK305884A (da) * 1983-06-24 1984-12-25 Yamanouchi Pharma Co Ltd Phenoxyderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4968707A (en) * 1987-06-10 1990-11-06 Pfizer Inc. Oxazolidin-2-one derivatives as hypoglycemic agents
GB8713861D0 (en) * 1987-06-13 1987-07-15 Beecham Group Plc Compounds
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US4997948A (en) * 1989-10-27 1991-03-05 American Home Products 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
ES2059121T5 (es) † 1990-02-09 2000-12-01 Upjohn Co Uso de agentes sensibilizantes de la insulina para tratar la hipertension.
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
DE69132713D1 (de) * 1990-04-27 2001-10-11 Sankyo Co Benzylidenthiazolidinderivate, ihre Herstellung und ihre Anwendung als Lipidperoxid-Inhibitoren
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
EP0579733B1 (en) * 1991-04-11 2001-06-20 PHARMACIA & UPJOHN COMPANY Thiazolidinedione derivatives, production and use thereof
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
AU679572B2 (en) * 1993-09-15 1997-07-03 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of NIDDM
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
SK280914B6 (sk) * 1994-03-08 2000-09-12 American Home Products Corporation Tiazolidíndiónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
DE69530501D1 (de) * 1994-10-20 2003-05-28 Nippon Chemiphar Co Chinolinderivat
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
AU5121796A (en) * 1995-05-08 1996-11-29 Nippon Chemiphar Co. Ltd. 2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
EP0783888A1 (en) 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
WO1998020871A1 (en) * 1996-11-08 1998-05-22 Nippon Chemiphar Co., Ltd. Visceral fat lowering agent
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
WO1999030739A1 (en) * 1997-12-16 1999-06-24 Sankyo Company, Limited Leukemia remedy
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
ATE365158T1 (de) 1999-04-28 2007-07-15 Inst Med Molecular Design Inc Pyrimidincarbonsäurederivate
WO2001002377A1 (en) * 1999-07-01 2001-01-11 Geron Corporation Telomerase inhibitors and methods of their use
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US7390824B1 (en) * 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
CN1215059C (zh) 1999-12-03 2005-08-17 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
DE60132723T2 (de) 2000-01-21 2009-01-29 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
CZ20023502A3 (cs) * 2000-04-25 2003-06-18 Kyorin Pharmaceutical Co., Ltd. Nová stabilní krystalická forma thiazolidionového derivátu a způsob jeho přípravy
WO2002024689A1 (en) 2000-09-21 2002-03-28 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
ATE341343T1 (de) * 2000-12-26 2006-10-15 Sankyo Co Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PT1355644E (pt) * 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
MEP27808A (en) * 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
NZ545332A (en) * 2001-01-26 2007-09-28 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
DK1757606T3 (da) * 2001-02-24 2009-09-07 Boehringer Ingelheim Pharma Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
JP4590159B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
EP1382336B1 (en) * 2001-04-25 2010-09-08 Takeda Pharmaceutical Company Limited Use of the abc expression promotor pioglitazone for the treatment of arteriosclerosis obliterans
EE200300519A (et) 2001-04-26 2004-02-16 L�civa, a.s. Meetod pioglitasooni kui suhkurtõvevastase aine saamiseks
BR0209711A (pt) * 2001-05-29 2004-11-03 Kyoto Pharma Ind Composto heterocìclico e seu uso medicinal
KR100874677B1 (ko) * 2001-05-29 2008-12-18 교토 야쿠힝 고교 가부시키가이샤 신규 복소환 유도체 및 그 의약 용도
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
MXPA04002572A (es) * 2001-09-21 2004-05-31 Schering Corp Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
AU2002337749A1 (en) * 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
AU2002366812A1 (en) * 2001-12-20 2003-07-09 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
US20050187258A1 (en) * 2001-12-20 2005-08-25 Ben-Zion Dolitzky Hydrogenation of precursors to thiazolidinedione antihyperglycemics
ITRM20020016A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
JPWO2003062427A1 (ja) * 2002-01-23 2005-05-26 山之内製薬株式会社 インスリン抵抗性改善薬のスクリーニング法
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003260813A1 (en) * 2002-09-12 2004-04-30 Themis Laboratories Private Limited Improved process for preparation of thiazolidinedione derivatives
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP2604266A1 (en) 2002-09-20 2013-06-19 Andrx Labs Llc Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CA2504878A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004108721A1 (en) * 2003-04-01 2004-12-16 Sun Pharmaceutical Industries Limited Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
ES2219180B1 (es) * 2003-05-09 2006-03-01 Medichem, S.A. Compuesto intermedio util para la preparacion de pioglitazona.
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
SI1622899T1 (sl) * 2003-05-13 2007-10-31 Synthon Bv Pioglitazonsulfat, farmacevtski sestavki in njihova uporaba
WO2004101560A1 (en) * 2003-05-13 2004-11-25 Synthon B.V. Processes for making thiazolidinedione derivatives and compounds thereof
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
JPWO2004106542A1 (ja) * 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
RS20050890A (sr) 2003-05-30 2007-12-31 Ranbaxy Laboratories Limited, Supstituisani pirol derivati
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005021542A2 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Process for the preparation of pioglitazone
WO2005021543A1 (en) * 2003-09-03 2005-03-10 Biocon Limited Phosphoric acid salt of 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP5140881B2 (ja) * 2003-09-17 2013-02-13 要 川杉 医薬組成物
CA2544309A1 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005080387A2 (en) * 2004-02-20 2005-09-01 Synthon B.V. Processes for making pioglitazone and compounds of the processes
CN102134230B (zh) * 2004-03-15 2019-06-28 武田药品工业株式会社 二肽基肽酶抑制剂
WO2005092382A1 (ja) * 2004-03-29 2005-10-06 Sankyo Company, Limited インスリン抵抗性改善剤を含有する糖尿病治療剤
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
US20060025478A1 (en) * 2004-07-27 2006-02-02 Keisuke Inoue Medicine for prevention or treatment of diabetes
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
WO2006022428A1 (ja) * 2004-08-26 2006-03-02 Takeda Pharmaceutical Company Limited 糖尿病治療剤
WO2006035459A1 (en) * 2004-09-28 2006-04-06 Morepen Laboratories Limited An improved process for the production of derivatives of thiozolidinediones and their precursors
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1874308A1 (en) * 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast for the treatment of diabetes mellitus
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
US20080319031A1 (en) * 2005-03-18 2008-12-25 Orchid Chemicals & Pharmaceuticals Limited Novel Tyrosine Derivatives
WO2006117654A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Processes for the preparation of pioglitazone or salts thereof
JPWO2007007757A1 (ja) * 2005-07-12 2009-01-29 第一三共株式会社 ＰＰＡＲγアゴニストを含有する医薬組成物
US20090203744A1 (en) * 2005-07-29 2009-08-13 Pande Y Surendrakumar Satyanarayan Novel pyridine derivatives
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ATE532518T1 (de) * 2005-09-14 2011-11-15 Takeda Pharmaceutical Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
WO2007054896A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin
NZ571872A (en) * 2006-03-16 2011-05-27 Metabolic Solutions Dev Co Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
CN101454006B (zh) * 2006-03-16 2012-12-26 新陈代谢解决方案开发公司 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
ES2654908T3 (es) * 2006-03-16 2018-02-15 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5323684B2 (ja) * 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
KR100791399B1 (ko) 2006-09-06 2008-01-07 동우신테크 주식회사 염산 피오글리타존의 제조방법
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2007334541A1 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (AISTM's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
WO2008075380A2 (en) * 2006-12-21 2008-06-26 Ind-Swift Laboratories Limited Process for the preparation of thiazolidine derivatives
WO2008091624A2 (en) * 2007-01-22 2008-07-31 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
KR101486091B1 (ko) * 2007-02-01 2015-01-23 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 피오글리타존을 포함하는 고형 제제
JP4866901B2 (ja) 2007-02-07 2012-02-01 協和発酵キリン株式会社 ３環系化合物
WO2008105326A1 (ja) * 2007-02-28 2008-09-04 Ohara Chemical Industries, Ltd. ２－イミノ－４－チアゾリジノン誘導体及び２，４－チアゾリジンジオン誘導体の製造方法
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2830073T3 (es) 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2963857A1 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
MX348799B (es) 2007-07-26 2017-06-29 Amgen Inc Enzimas aciltransferasa de lecitina-colesterol, modificadas.
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
WO2009035997A2 (en) * 2007-09-14 2009-03-19 Cara Therapeutics, Inc. Benzo-fused heterocycles
JP5371988B2 (ja) 2007-09-14 2013-12-18 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧を処置するためのチアゾリジンジオン類似体
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
RU2366421C2 (ru) * 2007-11-01 2009-09-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав для лечения диабета
US20090118514A1 (en) * 2007-11-06 2009-05-07 Raghupathi Reddy Anumula Processes for preparing pioglitazone and its pharmaceutically acceptable salts
JP5334422B2 (ja) * 2008-02-13 2013-11-06 株式会社トクヤマ ５−｛４−［２−（５−エチル−２−ピリジル）エトキシ］ベンジル｝−２−イミノ−４−チアゾリジノンの製造方法
JP5197063B2 (ja) * 2008-02-21 2013-05-15 株式会社トクヤマ ２−ブロモ−３−｛４−［２−（５−エチル−２−ピリジル）エトキシ］フェニル｝プロピオン酸メチルの製造方法
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009133576A1 (en) * 2008-04-28 2009-11-05 Erregierre S.P.A. A process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010016549A1 (ja) 2008-08-06 2010-02-11 協和発酵キリン株式会社 ３環系化合物
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
HRP20140709T1 (hr) 2008-08-12 2014-09-26 Zinfandel Pharmaceuticals, Inc. Postupak identifikacije faktora rizika za alzheimerovu bolest
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
WO2010026882A1 (ja) * 2008-09-02 2010-03-11 株式会社トクヤマ 脱臭化水素化抑制剤
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
CN102149669A (zh) * 2008-10-10 2011-08-10 株式会社德山 羰氧基化合物的制备方法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5473303B2 (ja) * 2008-12-01 2014-04-16 株式会社トクヤマ ２−ブロモ−３−｛４−［２−（５−エチル−２−ピリジル）エトキシ］フェニル｝プロピオン酸メチルの製造方法
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20110110766A (ko) * 2009-01-20 2011-10-07 가부시끼가이샤 도꾸야마 2-브로모-3-｛4-［2-（5-에틸-2-피리딜）에톡시］페닐｝프로피온산메틸의 탈브롬화 수소화를 억제하는 방법
JP2010208957A (ja) * 2009-03-06 2010-09-24 Tokuyama Corp 結晶構造を有する５−｛４−［２−（５−エチル−２−ピリジル）エトキシ］ベンジル｝−２−イミノ−４−チアゾリジノン及びその製造方法
CN102348457A (zh) 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
PL2445502T5 (pl) 2009-06-25 2023-03-13 Alkermes Pharma Ireland Limited Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych
JP5732453B2 (ja) * 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
RU2564661C2 (ru) 2009-12-15 2015-10-10 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
EP2552442A1 (en) 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
JP2013538807A (ja) 2010-09-01 2013-10-17 ルピン・リミテッド メトホルミンおよびピオグリタゾンを含む医薬組成物
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR102171747B1 (ko) 2011-01-10 2020-11-04 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
WO2012153312A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Process for the purification of pioglitazone
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
TW201311678A (zh) 2011-08-03 2013-03-16 Kyowa Hakko Kirin Co Ltd 二苯并氧呯衍生物
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
MX368200B (es) 2011-12-08 2019-09-24 Amgen Inc Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2638898A1 (en) 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Metformin and Pioglitazone Formulation with Different Release Profiles
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
HK1214760A1 (zh) 2012-11-05 2016-08-05 Commissariat à l'énergie atomique et aux énergies alternatives 用於消除体内血癌干细胞以及用於防止血癌复发的抗癌试剂如酪氨酸激酶和stat5拮抗剂优选为噻唑烷二酮的组合
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
WO2014150512A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Method and products for treating diabetes
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
US9815777B2 (en) 2013-09-22 2017-11-14 Jiva Pharma, Inc. Metformin salts to treat Type2 diabetes
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
KR101606547B1 (ko) * 2014-06-02 2016-03-28 김동연 공항 탑승객 위치조회시스템
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
EP3025707A1 (en) 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret A.S. A multilayer tablet comprising metformin and pioglitazone
KR102437685B1 (ko) 2016-06-08 2022-08-29 서포트-벤처 게엠베하 암 치료용 약학적 조합물
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
JP2019528273A (ja) 2016-08-17 2019-10-10 サポート−ヴェンチャー ゲゼルシャフト ミット ベシュレンクター ハフトゥング 聴力損失を予防又は治療する方法
TR201620309A2 (tr) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
KR20190137854A (ko) 2017-04-04 2019-12-11 스트리킨 아게 안과 질병의 예방 또는 치료 방법
WO2019154893A1 (en) 2018-02-08 2019-08-15 Strekin Ag Oral extended release pharmaceutical compositions for preventing or treating hearing loss
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US20210267983A1 (en) 2018-07-13 2021-09-02 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
CN111875598B (zh) * 2020-05-23 2023-10-10 白银京宇新药业有限公司 一种吡格亚胺的制备方法
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US20230263803A1 (en) 2020-08-11 2023-08-24 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders
CN116199739B (zh) 2020-09-30 2024-12-17 映恩生物制药（苏州）有限公司 一种抗肿瘤化合物及其制备方法和应用
EP4385502A1 (en) 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor
EP4385501A1 (en) 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途

Also Published As

Publication number Publication date
KR860005811A (ko) 1986-08-13
US4687777A (en) 1987-08-18
EP0193256A1 (en) 1986-09-03
FI81098C (fi) 1990-09-10
KR920010046B1 (ko) 1992-11-13
LU90719I2 (fr) 2001-03-26
GR860124B (en) 1986-05-19
BR1100325A (pt) 2000-06-27
ES8705886A1 (es) 1987-05-16
FI81098B (fi) 1990-05-31
DK21986D0 (da) 1986-01-17
PT81859B (pt) 1988-05-27
MY102016A (en) 1992-02-29
LV5779A4 (lv) 1996-12-20
CN86100411A (zh) 1986-07-16
SG105691G (en) 1992-02-14
IE58928B1 (en) 1993-12-01
IE860107L (en) 1986-07-19
PT81859A (en) 1986-02-01
NO163857B (no) 1990-04-23
HUT41775A (en) 1987-05-28
ZA86203B (en) 1987-09-30
AU5246786A (en) 1986-07-24
CA1277323C (en) 1990-12-04
DK21986A (da) 1986-07-20
DE10199018I1 (de) 2001-07-12
NO163857C (no) 1990-08-01
DE3662689D1 (en) 1989-05-11
ES550986A0 (es) 1987-05-16
ATE41931T1 (de) 1989-04-15
JPH0566956B2 (cg-RX-API-DMAC7.html) 1993-09-22
CN1003934B (zh) 1989-04-19
AR240698A1 (es) 1990-09-28
FI860232A0 (fi) 1986-01-17
MX9202933A (es) 1992-06-30
NL300038I2 (nl) 2001-05-01
DK171614B1 (da) 1997-02-24
EP0193256B1 (en) 1989-04-05
HK3692A (en) 1992-01-17
HU196795B (en) 1989-01-30
AU572719B2 (en) 1988-05-12
DE10199018I2 (de) 2006-02-02
FI860232L (fi) 1986-07-20
NO860141L (no) 1986-07-21
CS407991A3 (en) 1992-04-15
JPS61267580A (ja) 1986-11-27

Similar Documents

Publication Publication Date Title
LV5779B4 (lv) Tiazolidindiona atvasinajumi ar antidiabetiskam ipasibam
NL940006I1 (nl) 1,2-Benzisoxyzol-3-yl- en 1,2-benzisothiazol-3-yl-derivaten
DK292986A (da) Thiazoler
DK268285D0 (da) Dialkoxypyridinderivater
DK35785D0 (da) Tetrahydrocarbazolonderivater
DK243985D0 (da) Aminoalkylphenoxyderivater
DE3463503D1 (de) Sulfonamido-benzamide derivatives
DK575386D0 (da) Thiazolderivater
DE3566887D1 (de) Flavanon derivatives
DK524585D0 (da) Cholecalciferolderivater
DK443685A (da) Pirimidinderivater
DK109186A (da) Dihydropyridazinonderivater
DK320585A (da) Fluorallylaminderivater
DK491786A (da) Dichloranilinderivater
DK514585A (da) Aminoethylanilinderivater
DK556386A (da) Quinilinderivater
DE3666039D1 (de) Fulvalene derivatives
DK350989D0 (da) Tiazolderivater
DE3565100D1 (de) Cycloalkane-indene-carboximidamide derivatives
DK303886A (da) Secocanthinderivater
DK267190A (da) 13-substitueret-5-ketomilbemycinderivater
DE3662889D1 (de) Tetrahydrofurancarboxylic-acid derivatives
KR880700821A (ko) 데--데옥시테이코플라닌 유도체
DK54085A (da) Phenylpropargylaminderivater
DK237686D0 (da) Azolderivater